Please provide your email address to receive an email when new articles are posted on . The trial, which included 27 participants, met its safety and efficacy endpoints at 52 weeks and 76 weeks. The ...

Please provide your email address to receive an email when new articles are posted on . BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Paulo-Eduardo Stanga, MD, ...

- Company will advance RTx-021 for the treatment of geographic atrophy age-related macular degeneration SAN FRANCISCO--(BUSINESS WIRE)--Ray Therapeutics, a leading optogenetics company, announced ...

DALLAS, Dec. 2, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor ...

CNN — A blind man has had his vision partially restored using optogenetic therapy and engineered goggles -- the first successful case of such therapy in humans. Researchers treated a 58-year-old man ...

One of the hallmarks of cancer cells is their ability to evade apoptosis, or programmed cell death, through changes in protein expression. Inducing apoptosis in cancer cells has become a major focus ...

Dr. Christine N. Kay to Present Multivariant Analysis of 3-Year RESTORE and REMAIN Data, Identifying Patient and Disease Characteristics Associated with Best Outcomes in Retinitis Pigmentosa Patients ...

A blind man has had his vision partially restored using optogenetic therapy and engineered goggles -- the first successful case of such therapy in humans. Researchers treated a 58-year-old man who for ...

Presentations to highlight efficacy, durability, and safety of Nanoscope's optogenetic therapy platforms DALLAS, April 25, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotech company committed ...